Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
November 20, 2019updated 22 Nov 2019 9:44am

US regulator approves first contact lens to slow the onset of myopia in children

CooperVision's MiSight is the first FDA-approved contact lens designed for slowing myopic progression.

By GlobalData Healthcare

The US Food and Drug Administration (FDA) recently approved CooperVision’s MiSight, a contact lens indicated for the slow progression of myopia in children 8 to 12 years old.

This is the first FDA-approved contact lens designed for slowing myopic progression.

Juvenile-onset myopia

Myopia is nearsightedness, where a person is unable to clearly see objects that are far away. In many instances, myopia develops during childhood and continues to progress. Myopia is the most common type of visual impairment worldwide and its prevalence is on the rise. It can be corrected with glasses, contact lenses, or laser eye surgery.

Severe myopia in children increases the risk of developing other eye diseases in adulthood, such as retinal detachment and cataracts.

MiSight is a single-use daily soft contact lens that corrects visibility and also prevents the progression of myopia. The lens, like other soft contact lenses, is easy to use.

A three-year randomised clinical trial, which was conducted in four countries with an ethnically diverse sample, showed the lens was successful in slowing juvenile-onset myopia.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

Additionally, CooperVision says the lens achieved full-time wear among participants and that children have responded positively to the experience of using the lenses.

CooperVision Inc is a subsidiary of Cooper Companies Inc.

CooperVision manufactures a wide array of monthly, two-week and daily disposable contact lenses. Its products are available in over 100 different countries.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU